Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Document › Details

Illumina, Inc.. (8/17/23). "Press Release: Illumina Expands Genomics Capabilities in India with Opening of Solutions Center". San Diego, CA.

Region Region Bengaluru (Bangalore)
  Country India
Organisations Organisation Illumina Solutions Center, Bengaluru, India
  Group Illumina (Group)
  Organisation 2 Premas Life Sciences Pvt. Ltd.
Products Product DNA sequencing system
  Product 2 DNA sequencing technology
Index term Index term Premas Life Sciences–Illumina: genomic technology, 2007c– distribution Premas is channel partner in India
Persons Person Gupta, Praveen (Premas Life Sciences 202308 Founder + Chairman)
  Person 2 Weightman, Gretchen (Illumina 202308 SVP Asia-Pacific, Middle East + Africa)
     


Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India.


[photo]
Senior executives from Illumina and Premas Life Sciences cut the ribbon at Illumina’s India office inauguration. (L to R): Premas Life Sciences Founder & Chairman Avijit Das, Premas Life Sciences Founder & Managing Director Praveen Gupta, Illumina SVP Asia-Pacific, Middle East & Africa Gretchen Weightman, Illumina CFO and Chief Strategy & Corporate Development Officer Joydeep Goswami, Illumina India Country Manager Abhishek Gupta, Illumina Executive Territory Account Manager Niketa Pawar


Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent facility, Illumina will continue to collaborate with Premas to grow the genomics market in India, recognized by the United Nations as the most populous country in the world with more than 1.4 billion people. Expanding access to genomics in this important market will help unlock opportunities for advancing health care and combating the effects of climate change in South Asia.

"Expanding Illumina's presence in India allows the company to collaborate and be part of a vibrant biotech ecosystem with skilled labor, strong research and development resources, and supportive government policies," said Gretchen Weightman, senior vice president, Asia Pacific, Middle East & Africa. "In our 25th anniversary year, it's a very exciting time to be growing our physical presence in India to drive access and the further adoption of genomics to transform human health, particularly in oncology and infectious disease."

Tuberculosis is one infectious disease of concern and a prevalent problem in India. Globally, nearly 500,000 new cases of TB are detected each year, and India accounts for nearly 30% of those cases. Illumina has supported TB surveillance over the last seven years in India through the FIND Seq&Treat project, which aims to increase uptake of next-generation sequencing (NGS) for affordable, scalable, and rapid TB drug-susceptibility testing.

Illumina has also supported initiatives to increase access to sequencing capability in India; this includes philanthropic funding with the Bill & Melinda Gates Foundation and the Rockefeller Foundation to support COVID-19 surveillance.

Illumina employs over 30 people in India, in sales, operations, marketing, government relations, and human resources, and more hiring is expected as Illumina moves to scale operations there. The business is led by Abhishek Gupta, country manager. Gupta is responsible for achieving Illumina's commercial business objectives in India, spearheading the country's go-to-market strategy, managing relationships with primary stakeholders and key opinion leaders, and growing customer relationships.

"Abhishek brings vast knowledge and experience to Illumina India, and we look forward to supporting him and the team as they collaborate with and support our customers," said Weightman. She also emphasized the opportunity the new Solutions Center presents to pursue equitable access and more diverse data: "Democratizing genomics and making it available to the many and not just the few will take a collaborative approach. We must better reflect diversity in genomic data and drive awareness for, access to, and adoption of genomic technologies, through partnership."

The new Illumina Solutions Center features a fully equipped laboratory housing the latest NGS and array technologies, and it is fully resourced with field applications and service engineers to offer Illumina's partners and customers broad genomics capabilities. The center will support Illumina's growing number of channel partners in the region by providing training and education to increase local technical expertise and access to genomics.


About Illumina

Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
David McAlpine
347-327-1336
PR@illumina.com

   
Record changed: 2024-01-20

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Illumina (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top